A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis

OBJECTIVE: In disease‐modifying antirheumatic drug–naive patients with early rheumatoid arthritis (RA) who had achieved sustained low disease activity (a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate of ≤3.2 at both week 40 and week 52) after 1 year of treatment with c...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Weinblatt, Michael E., Bingham, Clifton O., Burmester, Gerd‐Rüdiger, Bykerk, Vivian P., Furst, Daniel E., Mariette, Xavier, van der Heijde, Désirée, van Vollenhoven, Ronald, VanLunen, Brenda, Ecoffet, Cécile, Cioffi, Christopher, Emery, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Rheumatoid Arthritis
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5656933/
https://ncbi.nlm.nih.gov/pubmed/28666080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40196
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados